IRIDEX (NASDAQ:IRIX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX) in a research report report published on Wednesday. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Stock Performance

IRIDEX stock opened at $1.70 on Wednesday. IRIDEX has a fifty-two week low of $1.27 and a fifty-two week high of $3.65. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54. The stock has a market cap of $28.29 million, a P/E ratio of -2.54 and a beta of 0.81. The firm’s fifty day moving average price is $1.64 and its 200-day moving average price is $1.89.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The firm had revenue of $11.58 million for the quarter. During the same quarter last year, the firm earned ($0.11) EPS.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.